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Abstract
Background: The Impella is a percutaneous ventricular assist device (pVAD) that provides temporary hemodynamic
support to patients with cardiogenic shock or for protected percutaneous coronary intervention. The manufacturer
recommends a 50-U/mL concentration of heparin purge solution (or 25 U/mL as an alternative), with systemic heparin to
maintain therapeutic anticoagulation during device support. Concomitant use of systemic heparin with the purge solution
may increase the risk of bleeding. Objectives: The primary objective of this study was to describe the prevalence of
thrombosis and bleeding using a less-concentrated heparin purge solution (25 U/mL) in combination with systemic heparin
therapy. Methods: This was a retrospective observational cohort study of patients who required at least 12 hours of
pVAD support and received 25-U/mL concentration of heparin purge solution between January 1, 2014, and May 31, 2017.
The primary end points were the rate of thrombotic and bleeding events. Secondary end points included the percentage
of time within the therapeutic activated partial thromboplastin time (aPTT) range. Descriptive statistics were utilized for
data analysis. Results: Of the 161 patients screened, 100 met inclusion criteria; 63% of patients experienced a bleeding
event, with Bleeding Academic Research Consortium (BARC) type 3a being the most common. Median percentages of
subtherapeutic and supratherapeutic aPTT values were similar between the bleeding and nonbleeding groups. Two patients
experienced thrombotic events. Conclusion and Relevance: Based on our findings, the device thrombosis rate was 2%
and the rate of major bleeding (BARC 3a and higher) was 35%. This study provides descriptive outcomes data of a lowerconcentration heparin purge solution.
Keywords
percutaneous ventricular assist device, heparin, purge, ventricular support device

Introduction
The Impella device (Abiomed, Danvers, Europe) is a
percutaneously inserted ventricular assist device (pVAD)
indicated for hemodynamic support during high-risk percutaneous coronary interventions and cardiogenic shock in the
setting of acute myocardial infarction (AMI) or severe heart
failure. To maintain adequate purge pressure and prevent
clot formation in the pVAD motor, a heparin-based purge
solution that runs retrograde to the direction of blood flow
is required. The manufacturer has historically recommended
a purge solution using dextrose in water with heparin
(50 U/mL) and systemic unfractionated heparin to provide
optimal anticoagulation.1 Recently, their recommendations
were updated to include a heparin purge solution of
25 U/mL as an alternative option. However, no data exist
describing the incidence of thrombosis or bleeding with the

lower heparin purge solution. Concomitant use with a heparin-based purge solution may pose a potential risk of
excessive heparin exposure. Moreover, these patients are
critically ill and likely carry other risk factors for bleeding,
such as acute liver injury, recent myocardial infarction
requiring stent placement and antiplatelet therapy, and
chronic liver disease.2,3 Finally, the automatic rate adjustment of the heparin purge solution by the pVAD controller
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may lead to unintended and unpredictable delivery of heparin, complicating management of systemic heparin therapy
and potentially resulting in supratherapeutic exposure.
A previous case series conducted at our institution,
which included 4 patients on a less-concentrated purge
solution of heparin 25 U/mL in 5% dextrose, did not result
in any bleeding episodes, thromboembolic events, or device
thrombosis.4 We hypothesized that a less-concentrated heparin purge solution would reduce variability in the delivery
of heparin, thereby decreasing the risk of supratherapeutic
heparin exposure and iatrogenic bleeding.4 In another case
series, 12 patients requiring pVAD support outside the catheterization laboratory were evaluated for supratherapeutic
activated partial thromboplastin times (aPTTs) while receiving heparinized 50 U/mL purge solution without systemic
heparin.5 Secondary outcomes included controller-mediated adjustments to the concentration of heparin purge solution, bleeding, and thrombotic events. Five patients had
supratherapeutic aPTTs, 3 of whom required a decrease in
the heparin purge solution concentration to 25 U/mL. Three
patients experienced bleeding events. Because of the paucity of current data, this study was conducted in a larger
population of patients who received a lower concentration
of heparinized purge solution. The purpose of this study
was to examine the safety and efficacy of a less-concentrated heparin purge solution (25 U/mL) in combination
with systemic heparin therapy.

by the following criteria: patients who underwent pump
replacement, motor or pump thrombosis not requiring pump
exchange, left-ventricular thrombosis, line clots, or receipt
of tissue plasminogen activator for motor thrombosis.
Secondary end points were percentage of patient time spent
inside and outside of the protocol-specified therapeutic
aPTT range. Events were recorded at the first occurrence.

Methods

Data Collection

Study Population

The electronic medical records of pVAD-supported patients
who were hospitalized between January 1, 2014, and May
31, 2017, were reviewed for inclusion. Baseline demographics collected included sex, years of age, heparin dosing weight, days of Impella support, and hemoglobin value
prior to initiating pVAD support. Relevant past medical
history for factors that increased the risk of bleeding was
collected: history of gastrointestinal bleed, intracranial
hemorrhage, intraocular hemorrhage, recent surgery within
the past 6 months, peptic ulcer disease, liver disease, international normalized ratio (INR) greater than 1.7 prior to
initiation of pVAD support, or coagulopathies (factor V
Leiden deficiency, platelet count less than 75 000/µL prior
to pVAD initiation, hemophilia, or von Willebrand factor
deficiency). Information about concomitant medications
that increase bleeding risk was also collected: direct-acting
oral anticoagulants, antiplatelet agents (aspirin, clopidogrel,
prasugrel, ticlopidine, ticagrelor, cangrelor, cilostazol, or
dipyridamole), or warfarin. Lactate dehydrogenase values
during pVAD support were collected if available. Data on
the indication for pVAD placement and the type of pVAD
placed were collected. Evaluation of thrombotic and bleeding events were identified by a combination of structured
keyword search (eg, thrombosis, clot, bleed, ooze) and

This study was an institutional review board–approved, retrospective cohort analysis of patients at a large urban teaching hospital. Patients were included if they were at least 18
years of age, required at least 12 hours of pVAD support,
and received a heparin-based purge solution. pVAD support
devices included the following: Impella 2.5, Impella CP,
Impella 5.0, and Impella RP. Exclusion criteria included
history of heparin-induced thrombocytopenia, pregnancy,
pVAD use limited to the catheterization laboratory, pVAD
purge solution without heparin or with an alternative anticoagulant, or missing data points.

End Points
Primary end points were the proportion of patients who
experienced thrombotic and bleeding events. The Bleeding
Academic Research Consortium (BARC) definition was
used to categorize bleeding events.4 The BARC definition is
a 5-level categorical classification system based on the temporizing measures required for and the setting of the bleeding event. For this study, bleeding events were defined as
BARC types 1 through 5. Thrombotic events were defined

Impella Protocol
At our institution, we implemented an anticoagulation protocol for patients with pVAD support. The standard purge
solution for the pVAD device was heparin 12 500 U/500 mL
(25 U/mL) in 5% dextrose. Dextrose concentration could be
increased to 10% or 20% if necessary to achieve the manufacturer-recommended purge pressure of 300 to 700 mm Hg
but was not adjusted in response to anticoagulation monitoring parameters. Systemic heparin was adjusted based on
the institutional protocol for patients who require pVAD
support, as described in the appendix. Our institution utilizes 2 heparin protocols: high intensity and low intensity.
The high-intensity protocol has an aPTT target of 64 to 109
s, which correlates to an AntiXa range of 0.3 to 0.7 U/mL
and is reserved for acute pulmonary embolism or deep vein
thrombosis. Patients on an Impella device are initiated on
the low-intensity heparin protocol, with a lower aPTT target
of 55 to 75 s.
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Table 1. Baseline Characteristics, Concomitant Medications, and Comorbidities That Increase Bleed Risk.
Characteristics

Bleeding events (n = 63)

Male, n (%)
41 (65)
Age, median (IQR), years
66 (57-76)
Weight, median (IQR), kg
83 (73.7-103.3)
Hemoglobin, median (IQR), g/dL
11.7 (10-13.1)
Documented history of major bleeding, n (%)
2 (3.2)
Indication for pVAD placement, n (%)
Acute decompensated heart failure
21 (33.3)
Acute myocardial infarction
33 (52.4)
Cardiac surgery: CABG
0 (0)
Cardiac surgery: valve replacement
4 (6.4)
Other
5 (7.9)
Impella device, n (%)
Impella 2.5
4 (6.3)
Impella CP
43 (68.3)
Impella 5.0
10 (15.9)
Impella RP
4 (6.3)
Multiple Impella devices
2 (3.2)
Concomitant medications that increase risk of bleeding, n (%)
Aspirin monotherapy
17 (27)
P2Y12 inhibitor monotherapy
2 (3.2)
Dual antiplatelet therapy
33 (52.4)
Comorbidities that increase risk of bleeding, n (%)
INR > 1.7 prior to initiation of pVAD
20 (32)
Active chronic liver disease
1 (1.6)
Peptic ulcer disease
0 (0)
Active coagulopathy
6 (9.5)

No bleeding events (n = 37)
27 (73)
68 (59-75)
89.2 (81.8-105.6)
11.3 (9.8-12.9)
2 (5.4)

P value
0.51
0.77
0.09
0.68
0.52

15 (40.6)
18 (48.6)
1 (2.7)
0 (0)
3 (8.1)

0.48

1 (2.7)
28 (75.7)
6 (16.2)
2 (5.4)
0 (0)

0.87

9 (24)
0 (0)
18 (48.6)

0.82
n/a
0.84

9 (24)
0 (0)
0 (0)
5 (13.5)

0.45
1
1
0.53

Abbreviations: CABG, coronary artery bypass grafting; INR, international normalized ratio; IQR, interquartile range; pVAD, percutaneous ventricular
assist device.

manual review of each patient’s progress notes and laboratory data.
aPTT values were considered evaluable if the laboratory
specimens were obtained while the patient was receiving
both systemic heparin and heparinized purge solution.
Percentage of aPTT values within the therapeutic range (5575 s) was determined by dividing the number of therapeutic
aPTT values by the number of evaluable aPTT measurements for each patient. Analysis was conducted using
descriptive statistics and completed using Microsoft Excel
2013.

Results
A total of 161 patients were screened for inclusion, 100 of
whom were included in the study. The most common reason
for exclusion was use of pVAD for less than 12 hours (n =
32), followed by patients transferred from an outside institution already on pVAD therapy (n = 19) and other exclusion criteria (use of purge without heparin, alternative
anticoagulant in purge solution, missing data points; n =
10). In all, 68% of patients were male, and the median age

was 67 years; 51% of patients were placed on pVAD support secondary to an AMI (Table 1). Of the 100 patients, a
majority were on antiplatelet therapy: 25% were on aspirin
monotherapy, and 51% were on dual antiplatelet therapy
with the following breakdown for the P2Y12 inhibitor—35
patients were on clopidogrel, 14 patients were on ticagrelor,
and 2 patients were on prasugrel. Table 1 describes other
concomitant disease states observed in these patients.
Patients were on pVAD for a median (IQR) of 59 hours
(12-95). Most patients had an Impella CP (71%), followed
by Impella 5.0 (16%), Impella RP (6%), and Impella 2.5
(5%). Two patients (2%) had 2 pVAD devices placed. The
median (IQR) unfractionated heparin (UFH) purge and systemic infusion administration was 3.4 (2.6-4.6) and 5.1
(3.6-7.1) U/kg of total body weight per hour, respectively,
with a net infusion rate (including both potential sources of
heparin) of 8.8 (6.7-11.3) U/kg/h. The percentage of aPTT
values within range per patient was 44.5% (17.5-60). In all,
63% of patients experienced a bleeding event, with BARC
type 3a cases comprising the majority of bleeding events
(26%), followed by type 1 and 2 (14% each), and type 3b
(9%). No patient met criteria for BARC types 3c, 4, or 5
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Figure 1. Median percentage of activated partial thromboplastin time (aPTT) values for patients with bleeding and without bleeding
events (n, number of patients out of 100).

Figure 2. Median percentage of activated partial thromboplastin time (aPTT) values for patients based on Bleeding Academic
Research Consortium (BARC) bleeding subtype (n, number of patients out of 100).

bleeding. Figure 1 illustrates the median percentage of
aPTT values for patients with and without bleeding events,
and Figure 2 illustrates the median percentage of aPTT

values for patients based on BARC bleeding subtypes that
did not demonstrate a relationship between aPTTs and
bleeding. At least 1 lactate dehydrogenase value was
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Table 2. Heparin Dosages for Purge and Systemic Infusion Between Patients With and Without Bleeding Events.
Characteristic
Purge solution heparin exposure, median (IQR), U/kg TBW/h
Systemic heparin exposure, median (IQR), U/kg TBW/h
Total heparin exposure, median (IQR), U/kg TBW/h
Purge solution heparin exposure, median (IQR), U/h
Systemic heparin exposure, median (IQR), U/h
Total heparin exposure, median (IQR), U/h

Patients with bleeding
event (n = 63)
3.6 (2.8-4.6)
4.7 (3.3-6.7)
8.7 (6.7-10.2)
296.0 (243.7-356.1)
407.5 (244.2-587.6)
706.2 (542.9-947.1)

Patients without bleeding
event (n = 37)
3.3 (2.1-4.5)
6.2 (3.7-8.4)
9.5 (6.9-12.8)
297.1 (205.5-402.4)
530.5 (348.7-756.6)
930.1 (598.6-1084.5)

P value
0.359
0.119
0.203
0.997
0.080
0.109

Abbreviations: IQR, interquartile range; TBW, total body weight.

obtained for 48 patients and the highest value was recorded,
with the median and interquartile range being 1140 IU/L
(634-2224) for patients without bleeding events and 919
IU/L (613-2079) for patients with bleeding events. Two
patients experienced a thrombotic event, both of which are
described further in the Discussion section.
An analysis of patients with bleeding events versus those
without bleeding revealed no significant differences in heparin dosages (Table 2). Of note, patients who did not experience a bleeding event had numerically higher systemic
heparin exposure, resulting in a higher total heparin exposure overall. The median percentage of therapeutic aPTT
values per patient was 40% for patients without bleeding
events and 45% for patients with bleeding events. The percentages of aPTT values per patient that were supratherapeutic or subtherapeutic were similar between the bleeding
and no bleeding subgroups.
A post hoc logistic regression was performed to establish
known or potentially associated predictors of bleeding
events (any severity and BARC 3a or worse) for the study
population. Thrombotic events were not modeled, because
of their low prevalence. Baseline or clinical characteristics
preceding bleeding outcomes included in explanatory models were VAD indication, VAD type, baseline INR, presence
of coagulopathy, duration of VAD support, percentage aPTT
values in range, and concomitant antiplatelet or anticoagulant therapies. Candidate variables were incorporated in a
hierarchical fashion based on data availability, biological
plausibility, and established clinical knowledge; stepwise
methods using covariate P value thresholds were not used.
All constructed models of bleeding events, especially bleeding of any severity, demonstrated poor precision and unclear
directionality and were not useful for descriptive purposes.

Discussion
The practice of anticoagulation for the Impella varies significantly in the United States. A recent survey by Reed
et al6 reports that 52.4% of centers used the recommended
manufacturer heparin purge concentration of 50 U/mL, and
41% of centers used lower heparin purge concentrations of

12.5 to 25 U/mL. To our knowledge, this is the first study
to publish results on the incidence of bleeding and thrombosis of utilizing a lower-concentration heparin purge solution in patients requiring pVAD support. Based on the
results of this study, a lower concentration of heparinized
purge solution seems to confer low thrombotic events in
these high-risk, critically ill patients. However, no definitive conclusions can be made because of the descriptive
nature of this study. Of the 63 individuals who experienced
a bleeding event, 35% experienced a major bleeding event
(BARC type 3a/3b). Additionally, one-third of these individuals had concomitant comorbidities that increased the
risk of bleeding (Table 1), 29% of patients had an INR
>1.7 prior to initiation of pVAD, and the majority were on
either dual antiplatelet therapy or aspirin monotherapy.
Therefore, most of our patients had a higher baseline risk
for bleeding prior to initiation of heparin therapy.
Interestingly, we found that patients in the bleeding
group had numerically lower systemic heparin exposure
than the nonbleeding group. We suspect that this is a result
of conservative management because of known or suspected bleeding events. Our management of bleeding with
the Impella is to decrease the rate of heparin infusion for
supratherapeutic aPTT, hold systemic heparin for significant bleeding, or maintain lower dose to avoid worsening
bleeding. Because of limitations with retrospective chart
review, we are unable to provide an accurate assessment of
the clinical decision made in regard to heparin adjustments
in the bleeding group. However, the lower systemic heparin
dose seems to align with clinical practice in patients with
bleeding events. In addition, the bleeding group also had a
higher percentage of patients with supratherapeutic aPTT
(Figure 1). As a result, the heparin dosage would have to be
decreased per protocol. With 63% of overall bleeding incidents and 35% with major bleeding, it would seem appropriate that the bleeding group has a slightly lower systemic
heparin infusion dose.
A recent cohort study found significantly higher risk of
in-hospital major bleeding with use of microaxial left VAD
(LVAD) when compared with use of intra-aortic balloon
pumps (31.3% vs 16.0%; P < 0.001), with both access site
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and non–access site bleeding higher in the LVAD group.
These results were consistent when a variable analysis was
conducted among patients with cardiogenic shock secondary to AMI.7 There were similar rates of major bleeding
comparing our current study with the recently published
cohort study by Dhruva et al.7 When considering these
critically ill patients who are already at a high risk of bleeding, initiation of a higher-concentration purge solution may
potentially place them at even greater risk of bleeding
events.
One of the patients who experienced a thrombotic event
in our study was a 32-year-old man with past medical history significant for nonischemic cardiomyopathy, chronic
systolic heart failure (ejection fraction 20%), and portal
vein thrombosis who was transferred to our institution for
evaluation of advanced heart failure therapies. He was
placed on a pVAD secondary to cardiogenic shock because
of his advanced heart failure. Of note, aPTTs measured
while the patient was on the pVAD were all supratherapeutic. After 27 hours of pVAD use, the motor was clotted, and
the patient was subsequently transitioned to a venoarterial
extracorporeal membrane oxygenation device for hemodynamic support. The providers attributed the motor clot to
an acute coagulopathy caused by multiorgan failure in
addition to a hypercoagulable state at baseline, for which
the workup was incomplete because the patient’s clinical
condition continued to decline despite maximal support.
Because he was no longer a candidate for a permanent
LVAD, the decision was made to withdraw support and initiate comfort measures only.
The second patient who experienced a thrombotic event
in our study was a 62-year-old man who transferred to our
facility with cardiogenic shock secondary to acute decompensated heart failure. A week after the pVAD was placed
for support, the device appeared to be clotted. The patient
was taken to the catheterization lab, where the device was
noted to have flow obstruction and required an exchange.
The aPTTs were within range prior to and during the time of
the exchange. Unfortunately, the patient passed away later
before a full workup could be completed to investigate the
cause of the clot.
Strengths of this study include a fairly large sample size.
However, it is important to note that this study was retrospective and descriptive in design and, therefore, is only
hypothesis generating. Because this was a retrospective
study, we were unable to determine the exact cause of the
bleeding events that occurred. There may have been other
confounders that could have increased the risk of bleeding,
such as critical illness, liver dysfunction, or other concomitant medications (ie, glycoprotein IIb/IIIa inhibitors in postMI patients). However, since the implementation of
ticagrelor to our STEMI protocol, utilization of glycoprotein IIb/IIIa inhibitor is minimal. Any administration of glycoprotein IIb/IIIa inhibitor is from a single bolus and
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unlikely to have a long-lasting effect for the duration of the
Impella device.

Conclusion and Relevance
Within our study, 2% of patients experienced a thrombotic
event involving the pump motor. Of the 63 bleeding events,
35 patients had clinically relevant bleeding (BARC 3a and
3b). Balancing the percentage of thrombosis versus that of
bleeding events even with a lower-concentration purge
solution suggests that additional bleeding avoidance measures should be investigated. Finally, our study provides
descriptive outcomes data of a lower-concentration heparin
purge solution.

Appendix
Impella Protocol
Manufacturer instructions for the pVAD recommend anticoagulation targets based on the activated clotting time;
however, because of feasibility, systemic intravenous (IV)
heparin is adjusted to achieve a goal aPTT of 55 to 75 s
using a nurse-driven protocol. Bolus doses of IV heparin are
not included in the protocol, to reduce the risk of bleeding.
For protocol-based rate adjustments of the systemic IV heparin infusion, the heparin purge solution rate (in units per
hour) is subtracted from the total IV heparin infusion rate.
Any further adjustments is made to the systemic IV heparin
infusion only. The aPTT is monitored every 6 hours for
patients receiving both systemic and purge-based sources of
heparin. For example,
A 75-kg female patient is admitted to the cardiovascular ICU
(CVICU) with an Impella device in place. Her heparin purge
solution is being delivered at 500 units (20 mL) per hour.
Based on the heparin protocol, her net IV heparin infusion
rate would be 900 units (12 U/kg body weight) per hour. The
nurse would, therefore, administer the systemic IV heparin
infusion at 400 U/h, for a final net rate of 900 U/h (heparin
purge source of 500 U/h plus systemic IV heparin source of
400 U/h).
As previously noted, the pVAD controller automatically adjusts
the purge solution to maintain adequate purge pressure for the
device. The nurse will make hourly assessments of the purge
solution rate and make necessary adjustments to systemic IV
heparin infusion rate in order to maintain the intended net
hourly dose of heparin. For example,
For the previous case, the patient’s first aPTT value result after
heparinization is 47 s. Based on the heparin protocol, the nurse
will increase the systemic IV heparin infusion rate by 100 U/h,
for a new final net infusion rate of 1000 U/h (heparin purge
source of 400 U/h plus systemic IV heparin source of 600
U/h). Hourly adjustments will then be made to the systemic IV
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heparin infusion until the next aPTT monitoring occurs 6
hours later.

For patients who require simultaneous left and right pVAD
support, the nurse will have to account for the total amount
of heparin the patient is receiving from both purge solutions. For example,
An 83-kg female patient is admitted to the CVICU with
simultaneous biventricular support. Based on the heparin
protocol, her net IV heparin infusion rate would be 1000 units
(12 U/kg body weight) per hour. Her left heparin purge solution
is being delivered at 400 units (16 mL) per hour and her right
heparin purge solution is at 300 units (12 mL) per hour. The
nurse would, therefore, administer the systemic IV heparin
infusion at 300 U/h, for a final net rate of 1000 U/h (left and
right heparin purge source of 400 and 300 U/h, respectively,
plus systemic IV heparin source of 300 U/h).

If the total hourly heparin exposure were too high based on
the patient’s weight, the nurse would contact the physician
to consider changing one of the purge solutions to a heparin-free dextrose product.
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